Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea

Launched by ASTRAZENECA · May 29, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a medication called tezepelumab (also known as Tezspire) for people with severe asthma in South Korea. The main goals of the study are to see how well this medication works and to understand any side effects that patients might experience while using it. The trial is not yet recruiting participants, but when it starts, it will include adults aged 18 and older who have received at least one dose of tezepelumab as prescribed by their doctor.

To be considered for this study, patients must have given their consent to participate, meaning they understand what the trial involves. However, those who are using tezepelumab for reasons not approved by health authorities or are currently involved in another clinical trial will not be eligible. Participants can expect to be monitored for their asthma symptoms and any side effects while taking the medication, helping researchers gather important information about its use in real-world settings.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients who are treated with at least one dose of tezepelumab according to the indication in the locally approved prescribing information
• • 2. Patients with evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study
• Exclusion Criteria:
• • 1. Other off-label indications according to the locally approved prescribing information
• • 2. Current participation in any interventional trial